Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil‑mediated promotion of DNA damage‑driven cytotoxicity
International Journal of Oncology · 2026
DOI: 10.3892/ijo.2026.5861 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Oncology, 2026. Verfasst von Elvira Mukinovic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Toxicology, Medical Faculty and University Hospital, Heinrich Heine University Duesseldorf, D‑40225 Duesseldorf, Germany. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Doxorubicin, Verapamil, Ovarian Neoplasms. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The efficacy of anticancer therapeutics is limited by acquired drug resistance of tumor cells. The present study aimed to characterize and overcome resistance mechanisms to the anthracycline derivative doxorubicin (Doxo). To this end, comparative analyses of Doxo‑induced stress responses of parental A2780 ovarian carcinoma cells and Doxo‑resistant A2780ADR variants were performed. A2780ADR cells revealed cross‑resistance to multiple compounds, including anticancer drugs [cisplatin (CisPt) and etoposide (Eto)] and DNA repair/DNA damage response (DDR) inhibitors (olaparib, niraparib, entinostat, prexasertib and rabusertib). A2780ADR cells formed markedly fewer DNA double‑strand breaks (DSB) following Doxo exposure compared with parental A2780 cells, resulting in a mitigated DDR, reduced proliferation inhibition and attenuated apoptosis. Potential resistance mechanisms identified to contribute to Doxo resistance of A2780ADR cells include increased Doxo efflux due to increased multi‑drug resistance gene 1 (MDR1) expression and reduced topoisomerase IIα protein expression. Substantial resensitization of A2780ADR cells to Doxo was achieved by both the RAC1 GTPase inhibitor EHT1864, the histone deacetylase inhibitor entinostat (EST) and, most effectively, the calcium channel blocker verapamil (Ver). Notably, Ver‑mediated sensitization also pertains to Eto and CisPt. The synergistic effect of Ver in combination with Doxo, which is reflected by low combination index (CI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Toxicology, Medical Faculty and University Hospital, Heinrich Heine University Duesseldorf, D‑40225 Duesseldorf, Germany.
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, D‑40225 Duesseldorf, Germany.
Zitieren
APA
Mukinovic, E., Federmann, S., Messling, L., Sekeres, M., Mann, J., Abbey, L., Kassack, M. U., & Fritz, G. (2026). Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil‑mediated promotion of DNA damage‑driven cytotoxicity. International Journal of Oncology. https://doi.org/10.3892/ijo.2026.5861
Vancouver
Mukinovic E, Federmann S, Messling L, Sekeres M, Mann J, Abbey L, et al. Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil‑mediated promotion of DNA damage‑driven cytotoxicity. International Journal of Oncology. 2026. doi:10.3892/ijo.2026.5861
BibTeX
@article{Mukinovic2026,
author = {Mukinovic, Elvira and Federmann, Sina and Messling, Larissa and Sekeres, Marlena and Mann, Julia and Abbey, Lena and Kassack, Matthias U and Fritz, Gerhard},
title = {Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil‑mediated promotion of DNA damage‑driven cytotoxicity},
journal = {International Journal of Oncology},
year = {2026},
doi = {10.3892/ijo.2026.5861}
}
EUVIMED